Base de dados : HANSEN
Pesquisa : PROGNOSTICO [Descritor de assunto]
Referências encontradas : 36 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 36 HANSEN  
              next record last record
seleciona
para imprimir
Id:23186
Autor:Boggild, Andrea K; Keystone, Jay S; Kain, Kevin C
Título:Leprosy: a primer for Canadian physicians
..-
Fonte:s.l; s.n; Jan. 2004. 8 p. ilus, tab.
Resumo:Leprosy is a rare but serious infectious disease caused by Mycobacterium leprae. While global prevalence of the disease is decreasing, increasing rates of immigration from countries where leprosy is endemic have led to the recognition of this illness in North America. Classically, leprosy presents as hypopigmented cutaneous macules along with sensory and motor peripheral neuropathies, although the clinical manifestations vary along a disease spectrum. In addition to primary infection, patients may undergo a [quot ]reaction,[quot ] an acute inflammatory response to the mycobacterium, which leads to pain and erythema of skin lesions and dangerous neuritis. Reactions can occur at any time during the course of leprosy, but they tend to be precipitated by treatment. They are a significant cause of impaired quality of life due to marked nerve damage and thus warrant prompt intervention. Although leprosy may have a protracted onset and be difficult to recognize, cure is achievable with appropriate multidrug therapy. Because untreated leprosy can result in permanent, irreversible nerve damage and secondary transmission, early diagnosis and treatment are essential to minimize morbidity. (AU).
Descritores:Diagnóstico Diferencial
Hanseníase/*/CL/DI/EP/TH
Prognóstico
Limites:HUMANO
Localização:BR191.1; 09330/s


  2 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:22742
Autor:Stefani, Mariane M. A; Martelli, Celina M. T; Gillis, Thomas P; Krahenbuhl, James L
Título:In situ type 1 cytokine gene expression and mechanism associated with early leprosy progression
..-
Fonte:s.l; s.n; 2003. 8 p. ilus.
Resumo:We explored the prognostic value of in situ cytokine patterns in 39 patients with single-skin-lesion paucibacillary leprosy before single-dose therapy, with 3 years of follow-up. Interferon (IFN)-gamma, interleukin (IL)-12, IL-10, IL-4, tumor necrosis factor (TNF)-alpha, and macrophage inflammatory protein (MIP)-1alpha mRNA was quantified in skin biopsy samples at diagnosis, and Mycobacterium leprae DNA was detected in 51.4% of cases. Type 1 immunity predominance with measurable IFN-gamma and undetectable IL-4, which is indicative of effective cell-mediated immunity, is compatible with both the reversal reactions (33.3%) and the resolution of lesions (64.1%) observed. A positive correlation between IL-12 and IFN-gamma indicated type 1 polarization via IL-12. The TNF-alpha/MIP-1alpha correlation implied the TNF-alpha induction of chemokines, which is important for granuloma formation. Positive correlations between key regulatory cytokines-IL-10 and IFN-gamma, IL-10 and IL-12, and IL-10 and TNF-alpha-suggests that there may be some level of an intralesional pro- or anti-inflammatory mechanism essential in avoiding immunopathology. (AU).
Descritores:Anticorpos Antibacterianos/BL
Biópsia
Estudos de Coortes
Citocinas/BI/*GE/IM
Regulação Bacteriana da Expressão Gênica/*IM
Hanseníase/DT/*GE/IM
Minociclina/TU
Mycobacterium leprae/*GE/IM
Ofloxacino/TU
Prognóstico
RNA Mensageiro/BI/GE
RNA Viral/BI/GE
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Rifampina/TU
Limites:Adolescente
Adulto
Criança
Feminino
Humano
Masculino
Células Th1/IM
Localização:BR191.1; 01884/s


  3 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-pt
Id:19226
Autor:Rabello Junior.
Título:Algumas observações relativas ao prognostico da lepra com utilidade para a conduta do tratamento.
Fonte:Rev. bras. Leprol;4(1):27-38, mar. 1936. .
Resumo:Uma therapeutica com base scientifica, para as molestias infectuosas chronicas repousar: 1) na escolha de substancias com actuação sobre o agente especifico (acção direta sobre as culturas, acção indirecta em animais experimentalmente innoculados),.....(AU).
Descritores:HANSENIASE
HANSENIASE/terap
PROGNOSTICO
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/1936/PDF/v4n1/v4n1a03.pdf - pt.
Localização:BR191.1


  4 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18940
Autor:Boonpucknavig, Vijitr; Soontornniyomkij, Virawudh
Título:Pathology of renal diseases in the tropics
..-
Fonte:s.l; s.n; Jan. 2003. 19 p. ilus.
Resumo:Renal diseases unique to the tropics are those that occur in association with infectious diseases including dengue hemorrhagic fever, typhoid fever, shigellosis, leptospirosis, lepromatous leprosy, malaria, opisthorchiasis, and schistosomiasis. These renal complications can be classified on the basis of their clinical and pathologic characteristics into acute transient reversible glomerulonephritis, chronic progressive irreversible glomerulonephritis, amyloidosis, and acute renal failure (ARF) resulting from acute tubular necrosis, acute tubulointerstitial nephritis, and thrombotic microangiopathy. Certain primary glomerular diseases including immunoglobulin (Ig) M nephropathy and focal segmental and global glomerulosclerosis are prevalent in some tropical countries. Renal complications of venomous snakebites also are common in the tropics. This article discusses and summarizes important works in the literature in respect to the clinical syndromes, pathologic features, and pathogenesis of tropical renal diseases both in humans and experimental animal models. (AU).
Descritores:DOENCAS TRANSMISSIVEIS/compl
DOENCAS TRANSMISSIVEIS/diag
GLOMERULOSCLEROSE FOCAL/etiol
GLOMERULOSCLEROSE FOCAL/patol
IMUNOHISTOQUIMICA
NEFROPATIAS/epidemiol
NEFROPATIAS/etiol
NEFROPATIAS/patol
NECROSE TUBULAR AGUDA/etiol
NECROSE TUBULAR AGUDA/patol
BIOPSIA POR AGULHA
NEFRITE INTERSTICIAL/etiol
NEFRITE INTERSTICIAL/patol
PREVALÊNCIA
PROGNOSTICO
INDICE DE GRAVIDADE DE DOENCA
TAXA DE SOBREVIVÊNCIA
FATORES DE RISCO
CLIMA TROPICAL/ef adv
Limites:HUMANO
MASCULINO
FEMININO
Meio Eletrônico: - .
Localização:BR191.1; 09109/s


  5 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18505
Autor:Seedat, Yackoob K
Título:Glomerular disease in the tropics
..-
Fonte:s.l; s.n; Jan. 2003. 9 p. .
Resumo:Glomerular disease in the tropics differs considerably from that in temperate climates and between the developed and the developing world. The prevalence and pattern of glomerular disease in the tropics in turn varies widely in different geographic regions and is influenced by environmental, nutritional, and socioeconomic factors. Among the infective agents that have been identified as contributing to an increased prevalence of glomerular disease in the tropics are Plasmodium malaria, Schistsomiasis mansoni, Mycobacterium leprosy, and hepatitis B virus (HBV). A decline in the prevalence can only be expected with the eradication of infections. Accurate knowledge of the prevalence, histologic features, and causes is essential to achieve prevention and management of glomerular diseases in the tropics. (AU).
Descritores:GLOMERULONEFRITE/diag
GLOMERULONEFRITE/epidemiol
GLOMERULONEFRITE POR IGA/diag
GLOMERULONEFRITE POR IGA/epidemiol
GLOMERULONEFRITE MEMBRANOSA/diag
GLOMERULONEFRITE MEMBRANOSA/epidemiol
NEFRITE LUPICA/diag
NEFRITE LUPICA/epidemiol
SISTEMAS DE MEDICACAO
CLIMA TROPICAL/ef adv
FATORES DE RISCO
INDICE DE GRAVIDADE DE DOENCA
PREVALÊNCIA
PROGNOSTICO
Limites:HUMANO
MASCULINO
FEMININO
Meio Eletrônico: - .
Localização:BR191.1; 09140/s


  6 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18035
Autor:Moran, C. J; Ryder, G; Turk, J. L; Waters, M. F
Título:Evidence for circulating immune complexes in lepromatous leprosy
..-
Fonte:s.l; s.n; September 16, 1972. 2 p. tab.
Resumo:Sera from patients with lepromatous leprosy react with the Clq component of complement in vitro. The incidence of sera that react in this way is higher in patients with active erythema nodosum leprosum (E.N.L.). This is further, although circumstantial, evidence for the immune complex aetiology of E.N.L. and opens a way for the more precise identification of the antigen involved.(AU).
Descritores:COMPLEMENTO
ERITEMA NODOSO/imunol
SOROS IMUNES
HANSENIASE/imunol
TESTES DE PRECIPITINA
PROGNOSTICO
COELHOS/imunol
COMPLEXO ANTIGENO-ANTICORPO
Limites:HUMANO
ANIMAL
Meio Eletrônico: - .
Localização:BR191.1; 01835/s


  7 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17993
Autor:Moran, C. J; Ryder, G; Turk, J. L; Waters, M. F. R
Título:Evidence for circulating immune complexes in lepromatous leprosy
..-
Fonte:s.l; s.n; sep. 1972. 2 p. tab.
Resumo:Sera from patients with lepromatous leprosy react with the Clq component of complement in vitro. The incidence of sera that react in this way is higher in patients with active erythema nodosum leprosum. (AU).
Descritores:COMPLEXO ANTIGENO-ANTICORPO
COMPLEMENTO
ERITEMA NODOSO/imunol
SOROS IMUNES
HANSENIASE/imunol
TESTES DE PRECIPITINA
PROGNOSTICO
COELHOS/imunol
Limites:HUMANO
ANIMAL
Meio Eletrônico: - .
Localização:BR191.1; 01272/s


  8 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17777
Autor:Saad, M. H; Medeiros, M. A; Gallo, M. E; Gontijo, P. P; Fonseca, L. S
Título:IgM immunoglobulins reacting with the phenolic glycolipid-1 antigen from Mycobacterium leprae in sera of leprosy patients and their contacts
..-
Fonte:s.l; s.n; Apr.-Jun. 1990. 4 p. tab.
Resumo:For the first time in Brazil it was investigated the occurrence of IgM anti-PGL-1 in the sera of household contacts of leprosy patients using the ELISA methodology. The sera of the multibacillary patients showed significantly more immuno-reactivity than from the paucibacillary patients. It was observed a high subclinical infection incidence among household contacts (19.4%). The percentage of leprosy development was 5% (1/21) among the seropositive contact group. This finding suggests that serology could be useful as prognostic test, but for better definition is necessary to test a population from endemic area for long period time.(AU).
Descritores:ELISA
SEGUIMENTOS
GLICOLIPIDIOS/anal
HANSENIASE/diag
HANSENIASE/imunol
IMUNOGLOBULINA M/anal
MYCOBACTERIUM LEPRAE/imunol
PROGNOSTICO
Limites:HUMANO
ADOLESCENTE
ADULTO
IDOSO
CRIANCA
FEMININO
MASCULINO
MEIA-IDADE
Meio Eletrônico: - .
Localização:BR191.1; 02104/s


  9 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16329
Autor:Muthukumar, Thangamani; Jayakumar, Matcha; Fernando, Edwin M; Muthusethupathi, Muthayeepalayam A
Título:Acute renal failure due to rifampicin: astudy of 25 patients
..-
Fonte:s.l; s.n; Oct. 2002. 7 p. ilus, tab.
Descritores:ANTIBIOTICOS ANTITUBERCULOSE
ANTIBIOTICOS ANTITUBERCULOSE
ESQUEMA DE MEDICAÇAO
INSUFICIENCIA RENAL AGUDA
INSUFICIENCIA RENAL AGUDA
INSUFICIENCIA RENAL AGUDA
HANSENIASE
OLIGURIA
PROGNOSTICO
RIFAMPINA
RIFAMPINA
TUBERCULOSE DOS LINFONODOS/DT
Localização:BR191.1; 08638/s


  10 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15657
Autor:Waters, Michael F. R; Jacobs, Jean M
Título:Leprous neuropathies
..-
Fonte:s.l; s.n; 1996. 27 p. ilus.
Descritores:HANSENIASE
HANSENIASE
BIOPSIA
DIAGNOSTICO DIFERENCIAL
NERVOS PERIFÉRICOS
DOENÇAS DO SISTEMA NERVOSO PERIFÉRICO
DOENÇAS DO SISTEMA NERVOSO PERIFÉRICO
PROGNOSTICO
Localização:BR191.1; 08432/s


  11 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15647
Autor:Mayorga Rodriguez, Jorge Arturo; Salas, Francisco Vargas; Ortiz, Roberto Morales; Estrada, Victor Fernando Muñoz; Vargas, Alejandro García; Gómez, José Fernando Barba
Título:Valoración baciloscópica en pacientes con enfermedad de Hansen, tratados con el esquema de la OMS
..-
Fonte:s.l; s.n; 1997. 2 p. tab.
Descritores:HANSENIASE
HANSENIASE
PROTOCOLOS CLINICOS
TÉCNICAS BACTERIOLOGICAS
QUIMIOTERAPIA
QUIMIOTERAPIA
PROGNOSTICO
ORGANIZAÇAO MUNDIAL DA SAUDE
Localização:BR191.1; 08420/s


  12 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15491
Autor:Chatterjee, Mitali; Jaffe, Charles L; Sundar, Shyam; Basu, Debasis; Sen, Sandeep; Mandal, Chitra
Título:Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India
..-
Fonte:s.l; s.n; 1999. 5 p. ilus, tab, graf.
Descritores:ANTICORPOS MONOCLONAIS
ANTICORPOS ANTIPROTOZOARIOS
GLUCONATO DE ANTIMONIO E SODIO
ANTIPROTOZOARIOS
REAÇOES CRUZADAS
ELISA
INDIA
LEISHMANIA DONOVANI
LEISHMANIOSE CUTANEA
LEISHMANIOSE CUTANEA
LEISHMANIOSE VISCERAL
LEISHMANIOSE VISCERAL
LEISHMANIOSE VISCERAL
LEISHMANIOSE VISCERAL
HANSENIASE
HANSENIASE
PROGNOSTICO
MALARIA
MALARIA
TUBERCULOSE
TUBERCULOSE
Limites:ANIMAL
Localização:BR191.1; 08342/s


  13 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15039
Autor:Anon
Título:Elimination of leprosy as a public health problem (update)
..-
Fonte:s.l; s.n; oct. 1998. 5 p. tab.
Descritores:LEPROSTATICOS
HANSENIASE
HANSENIASE
PREVALENCIA
PROGNOSTICO
SAUDE PUBLICA
FATORES DE RISCO
SAUDE MUNDIAL
ORGANIZAÇAO MUNDIAL DA SAUDE
Localização:BR191.1; 07281/s


  14 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14114
Autor:Jain, Sanjiv; Sehgal, Virendra N
Título:Multidrug therapeutic challenges in leprosy
..-
Fonte:s.l; s.n; 1997. 4 p. tab.
Descritores:ENSAIOS CLINICOS
ESQUEMA DE MEDICAÇAO
QUIMIOTERAPIA COMBINADA
INDIA
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE
HANSENIASE
HANSENIASE
PROGNOSTICO
RECIDIVA
RESULTADO DE TRATAMENTO
Localização:BR191.1; 07056/s


  15 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13944
Autor:Sampoonachot, Prasert; Kuhacharoen, Nunta; Kampirapap, Kowit; Bampenyu, Sawanee; Rungruang, Seri; Supanwanit, Sakchai; Bundit, Cahiwut; Peerapakorn, Arporn; Tiasiri, Sirisavapa; Surasondhi, Somchai; Wiriyawipart, Srisunthon
Título:Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients
..-
Fonte:s.l; s.n; 1996. 8 p. tab, graf.
Descritores:HANSENIASE
AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA
QUIMIOTERAPIA COMBINADA
SEGUIMENTOS
LEPROSTATICOS
LEPROSTATICOS
OFLOXACINA
OFLOXACINA
PROGNOSTICO
RIFAMPINA
RIFAMPINA
Localização:BR191.1; 06845/s


  16 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13745
Autor:Klatser, Paul R
Título:Serology of leprosy
..-
Fonte:s.l; s.n; 1994. 4 p. .
Descritores:LEPROSTATICOS
HANSENIASE
HANSENIASE
HANSENIASE
HANSENIASE
HANSENIASE
PROGNOSTICO
ESTUDOS SOROEPIDEMIOLOGICOS
TESTES SOROLOGICOS/MT
Localização:BR191.1; 06702/s


  17 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13646
Autor:Chou, Pesus; Tsai, Pao-Feng; Soong, Lin-Nor
Título:Analysis of factors related to treatment and prognosis of leprosy patients in southern Taiwan
..-
Fonte:s.l; s.n; 1993. 8 p. tab.
Descritores:LEPROSTATICOS
HANSENIASE
PROGNOSTICO
ANALISE DE REGRESSAO
FORMOSA
FATORES DE TEMPO
Localização:BR191.1; 06603/s


  18 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13525
Autor:Maman Junior, Italo; Baldi, Alexandre Busetti; Campos, Luis Carlos
Título:Hanseniase
Leprosy-
Fonte:Porto Alegre; s.n; 1994. 14 p. tab.
Descritores:SULFONAS
RIFAMPINA
CLOFAZIMINA
TALIDOMIDA
PREDNISONA
HANSENIASE
HANSENIASE
HANSENIASE
QUIMIOTERAPIA COMBINADA
DIAGNOSTICO DIFERENCIAL
ANTIGENO DE MITSUDA
PROGNOSTICO
Localização:BR191.1; 06261/s


  19 / 36 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:10231
Autor:Arbesfeld, Stuart J; Kurban, Amal K
Título:Behçet's disease: new perspectives on an enigmatic syndrome
..-
Fonte:s.l; s.n; 1988. 13 p. tab.
Resumo:Behçet's disease is a multifaceted syndrome characterized by oral and genital ulcerations and ocular abnormalities including keratitis, optic neuritis, and uveitis. The disease has multiple systemic associations that include involvement of the gastrointestinal, cardiovascular, and central nervous systems as well as the joints, blood vessels, and lungs. Infrequently observed in the Americas and Western Europe, it has been more commonly seen in Turkey and Japan. Human lymphocyte antigen (HLA)-Bw51, HLA-B27, and HLA-B12 have each been associated with various manifestations of Behçet's disease. Numerous etiologies have been proposed, including environmental, virologic, bacterial, and immunologic factors; an autoimmune basis, characterized by circulating immune complexes and complement activation, has gained increasing acceptance. Although tetracycline remains the drug of choice for the oral ulcers of Behçet's disease, topical corticosteroids and topical anesthetics have been used for both oral and genital involvement. Oral corticosteroids continue to be the mainstay of systemic therapy, although various immunomodulators and anti-inflammatory agents, such as azathioprine, cyclophosphamide, chlorambucil, colchicine, dapsone, and cyclosporine, have been employed successfully. (AU).
Descritores:SINDROME DE BEHCET/*/DI/DT/EP/ET
PROGNOSTICO
FATORES SEXUAIS
Limites:ADOLESCENTE
ADULTO
IDOSO
CRIANCA
FEMININO
HUMANO
MASCULINO
MEIA-IDADE
SUPPORT, NON-U.S. GOV'T
Localização:BR191.1; 0107/cme


  20 / 36 HANSEN  
              first record previous record
seleciona
para imprimir
Texto Completo-En
Id:9173
Autor:Alchorne, Mauricio M. A; Rotberg, Abrahao; Michalany, Jorge; Vargas, Paulo de O; Cassiano,Tupy P.
Título:Prognostic consideration base on study of 38 hanseniasis patients sumetted to Mitsuda tests 23 to 35 years previously.
Fonte:Hansen. Int;3(1):5-11, 1978. .
Resumo:Out of 2775 hanseniasis patients Mitsuda tested by one of the authors from 1933 to 1947, 38 where re-examined in 1970/1971. 28 had been treated regularly, 6 did not receive sulfones. Improvement or disappearance of dermatological lesions occurred in 31 (81,5 por cento), independently of reactivity. All eleven bacteriologically positive out of 19 Mitsuda negative bacteriologically negative, which is partly attributed to sulfones. One treated bacillary negative patient became positive. 28(76,3 por cento) were neurollogically aggravated, independently of reactivity but more evidently among the stronger reactors. As regards classification, all initially tuberculloid, virchovian and dimorphous patients continued in their types or group, but only 7(41,2 por cento) out of the 17 initially indetermined remained so. Four(23,5 por cento) two Mitsuda, two changed to reactional tuberculoid, 6(35,3 por cento), (Mitsuda) changed to the Virchowian type. these developments according to reactivity confirm the pathogenetic theory postulated in 1937 by one of the authors. Mitsuda reactivity remained generally unchanged, rarely increased or decreased. The good prognostic value of the strong Mitsuda test is generally confirmed, but only as regards classification, bacillation nad dermatological lesions, not form the neurological and social viewpoints..
Descritores:HANSENIASE
HANSENIASE
PROGNOSTICO
 ANTIGENO DE MITSUDA
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/hansenint/v01aov20/1978/PDF/v3n1/v3n1a01.pdf - En.
Localização:BR191.1



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information